Literature DB >> 34720146

Dexmedetomidine for Treatment of Delayed Peak Symptoms of Cannabis Withdrawal Syndrome: A Case Report.

Katie MacCamy1,2, Daniel Hu2.   

Abstract

Background: Cannabis withdrawal syndrome (CWS) is characterized by irritability, sleep disorders, and physical discomfort that typically peaks within 7 days of cessation. Case: A patient with a 30-year history of heavy cannabis developed prolonged symptoms of CWS that peaked at greater than 40 days after cessation, who was successfully managed with dexmedetomidine. Discussion: This case report documents an unusual case of significantly delayed CWS peak in symptoms, as well as the novel use of dexmedetomidine for inpatient management of CWS.
© The Author(s) 2020.

Entities:  

Keywords:  cannabis; cannabis use disorder; dexmedetomidine; withdrawal

Year:  2020        PMID： 34720146      PMCID： PMC8554615          DOI： 10.1177/0018578720919025

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  12 in total

Review 1.  Review of the validity and significance of cannabis withdrawal syndrome.

Authors:  Alan J Budney; John R Hughes; Brent A Moore; Ryan Vandrey
Journal:  Am J Psychiatry       Date:  2004-11       Impact factor: 18.112

2.  Use of dexmedetomidine to treat delirium primarily caused by cannabis.

Authors:  Jerrold B Leikin; Olga Amusina
Journal:  Am J Emerg Med       Date:  2016-10-11       Impact factor: 2.469

Review 3.  Cannabis, Cannabinoids, and Sleep: a Review of the Literature.

Authors:  Kimberly A Babson; James Sottile; Danielle Morabito
Journal:  Curr Psychiatry Rep       Date:  2017-04       Impact factor: 5.285

Review 4.  A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.

Authors:  Emily J Cox; Neha Maharao; Gabriela Patilea-Vrana; Jashvant D Unadkat; Allan E Rettie; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Ther       Date:  2019-05-07       Impact factor: 12.310

Review 5.  Dexmedetomidine.

Authors:  D B Coursin; D B Coursin; G A Maccioli
Journal:  Curr Opin Crit Care       Date:  2001-08       Impact factor: 3.687

Review 6.  The cannabis withdrawal syndrome.

Authors:  Alan J Budney; John R Hughes
Journal:  Curr Opin Psychiatry       Date:  2006-05       Impact factor: 4.741

7.  Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.

Authors:  David J Allsop; Jan Copeland; Nicholas Lintzeris; Adrian J Dunlop; Mark Montebello; Craig Sadler; Gonzalo R Rivas; Rohan M Holland; Peter Muhleisen; Melissa M Norberg; Jessica Booth; Iain S McGregor
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

Review 8.  A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.

Authors:  Maira Aguiar Werneck; Guilherme Trevizan Kortas; Arthur Guerra de Andrade; João Mauricio Castaldelli-Maia
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

9.  A cannabinoid-intoxicated child treated with dexmedetomidine: a case report.

Authors:  Flora Cipriani; Aldo Mancino; Silvia Maria Pulitanò; Marco Piastra; Giorgio Conti
Journal:  J Med Case Rep       Date:  2015-07-03

Review 10.  The cannabis withdrawal syndrome: current insights.

Authors:  Udo Bonnet; Ulrich W Preuss
Journal:  Subst Abuse Rehabil       Date:  2017-04-27
View more
  1 in total

Review 1.  Considerations for Cannabinoids in Perioperative Care by Anesthesiologists.

Authors:  Krzysztof Laudanski; Justin Wain
Journal:  J Clin Med       Date:  2022-01-22       Impact factor: 4.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.